Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCOA1 | Q15788 | 1/20 | 0.66 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA3 | P07451 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.42 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31345781 | 1.00 | NCOA1 (0.66) | NCOA1CA12LMNAMCL1CA9 | |
| SCHEMBL25366432 | 0.80 | NCOA1 (1.00) | NCOA1LMNAKDM4EMAPTCYP1A2 | |
| Coumarin SCHEMBL30733982 | 0.78 | CA12 (0.67) | NCOA1CA12LMNAMCL1CA9 | |
| Coumarin SCHEMBL1377362 | 0.78 | CA12 (0.67) | NCOA1CA12LMNAMCL1CA9 | |
| Coumarin SCHEMBL28314951 | 0.77 | CA12 (0.65) | NCOA1CA12LMNAMCL1CA9 | |
| Coumarin SCHEMBL28437330 | 0.75 | LMNA (0.64) | NCOA1CA12LMNAMCL1CA9 | |
| SCHEMBL31618839 | 0.73 | NCOA1 (0.50) | NCOA1CA12LMNAMCL1CA9 | |
| Coumarin SCHEMBL28291423 | 0.73 | CA12 (0.71) | NCOA1CA12LMNAMCL1CA9 | |
| SCHEMBL29506237 | 0.72 | MAPT (0.46) | NCOA1CA12LMNAMCL1CA9 | |
| SCHEMBL276699 | 0.72 | MAPT (0.46) | NCOA1CA12LMNAMCL1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116036080-B | Application of pyranopyridone compounds in preparation of medicines for treating liver cancer | 江西省林业科学院 | 2023-06-06 | — | — | CN | claimed |
| CN-116036080-A | Application of pyranopyridone compounds in preparation of medicines for treating liver cancer | 江西省林业科学院 | 2023-05-02 | — | — | CN | claimed |
| CN-121135735-A | Pyranopyridinone alkaloid, preparation method thereof and application thereof in preparation of antitumor drugs | 中国科学院南海海洋研究所 | 2025-12-16 | — | — | CN | disclosed |
| CN-119569744-A | Pyropyrrone alkaloid compound, and preparation method and application thereof | 武汉大学人民医院（湖北省人民医院） | 2025-03-07 | — | — | CN | disclosed |
| US-20240067633-A1 | KETOHEXOKINASE INHIBITOR AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20230365541-A1 | INHIBITOR OF ENHANCER OF ZESTE HOMOLOGUE 2, AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20230357193-A1 | COMPOUND CAPABLE OF INHIBITING AND DEGRADING ANDROGEN RECEPTORS, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL USES THEREOF | XIZANG HAISCO PHARMACEUTICALS CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357193-A1 | COMPOUND CAPABLE OF INHIBITING AND DEGRADING ANDROGEN RECEPTORS, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL USES THEREOF | XIZANG HAISCO PHARMACEUTICALS CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230219961-A1 | Pyridine acetamide derivative serving as CDK inhibitor, and preparation method therefor and use thereof | Suzhou Alphama Biotechnology Co., Ltd. (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20230192703-A1 | Polycyclic amide derivative as CDK9 inhibitor, preparation method therefor and use thereof | Suzhou Alphama Biotechnology Co., Ltd. (CN) | 2023-06-22 | — | — | US | disclosed |
| CN-116036080-B | Application of pyranopyridone compounds in preparation of medicines for treating liver cancer | 江西省林业科学院 | 2023-06-06 | — | — | CN | disclosed |
| US-7622451-B2 | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders | UNIVERSITY OF KANSAS (US) | 2009-11-24 | — | — | US | disclosed |
| US-7608594-B2 | Novobiocin analogues as anticancer agents | UNIVERSITY OF KANSAS (US) | 2009-10-27 | — | — | US | disclosed |
| US-20090247566-A1 | Pyrano [3,2-C] Pyridones and Related Heterocyclic Compounds as Pharmaceutical Agents for Treating Disorders Responsive to Apoptosis, Antiproliferation or Vascular Disruption, and the Use Thereof | NEW MEXICO TECHNICAL RESEARCH FOUNDATION | 2009-10-01 | — | — | US | disclosed |
| US-20090187014-A1 | Novobiocin Analogues | UNIVERSITY OF KANSAS | 2009-07-23 | — | — | US | disclosed |
| US-20090163709-A1 | Novobiocin Analogues Having Modified Sugar Moieties | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-06-25 | — | — | US | disclosed |
| US-20070270452-A1 | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-11-22 | — | — | US | disclosed |
| EP-1807440-A2 | NOVOBIOCIN ANALOGUES AS ANTICANCER AGENTS | The University of Kansas (US) | 2007-07-18 | — | — | EP | disclosed |
| US-20060199776-A1 | Novobiocin analogues as anticancer agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-09-07 | — | — | US | disclosed |
| WO-2006050501-A2 | NOVOBIOCIN ANALOGUES AS ANTICANCER AGENTS | UNIVERSITY OF KANSAS (US) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192703-A1 | Polycyclic amide derivative as CDK9 inhibitor, preparation method therefor and use thereof | CDK9, CDK8, CDK19 | NCOA1 136/4885CA12 2981/4885LMNA 3225/4885 |
| US-20230357193-A1 | COMPOUND CAPABLE OF INHIBITING AND DEGRADING ANDROGEN RECEPTORS, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL USES THEREOF | AR, CYP17A1, KLK3 | NCOA1 221/4885CA12 971/4885LMNA 1905/4885 |
| US-20090247566-A1 | Pyrano [3,2-C] Pyridones and Related Heterocyclic Compounds as Pharmaceutical Agents for Treating Disorders Responsive to Apoptosis, Antiproliferation or Vascular Disruption, and the Use Thereof | BAX, CASP3, CASP7 | NCOA1 902/4885CA12 4688/4885LMNA 374/4885 |
| US-20090163709-A1 | Novobiocin Analogues Having Modified Sugar Moieties | HSP90AB1, HSP90B1, HSP90AB2P | NCOA1 2953/4885CA12 3548/4885LMNA 4561/4885 |
| US-20230219961-A1 | Pyridine acetamide derivative serving as CDK inhibitor, and preparation method therefor and use thereof | CDK9, CDK7, CDK8 | NCOA1 313/4885CA12 2742/4885LMNA 3521/4885 |
| US-20070270452-A1 | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders | SSB, IAPP, NLN | NCOA1 4534/4885CA12 3744/4885LMNA 1526/4885 |
| US-20060199776-A1 | Novobiocin analogues as anticancer agents | HSP90B1, HSP90AB2P, HSP90AB1 | NCOA1 2432/4885CA12 3479/4885LMNA 2952/4885 |
| US-20230365541-A1 | INHIBITOR OF ENHANCER OF ZESTE HOMOLOGUE 2, AND USE THEREOF | EZH2, BMI1, EZH1 | NCOA1 320/4885CA12 2325/4885LMNA 3180/4885 |
| US-20240067633-A1 | KETOHEXOKINASE INHIBITOR AND USE THEREOF | KHK, GCK, HK1 | NCOA1 1830/4885CA12 2167/4885LMNA 3682/4885 |
| US-20090187014-A1 | Novobiocin Analogues | SSB, SSBP1, BTD | NCOA1 4137/4885CA12 3932/4885LMNA 1560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.